Management ChangeJul 7, 2026, 07:01 AM
Kymera Appoints Dr. Elizabeth Laws as SVP for KT-621 Program
AI Summary
Kymera Therapeutics announced the appointment of Dr. Elizabeth Laws as Senior Vice President, KT-621 Development Program Leader. Dr. Laws, a former immunology leader at Sanofi with over two decades of biopharmaceutical experience, will oversee the global development of Kymera’s first-in-class oral STAT6 degrader, KT-621. The company also provided updates on the KT-621 program, with Phase 2b trials advancing in atopic dermatitis and asthma, expecting data by year-end 2026 and late 2027, respectively, and planning Phase 3 trials in AD to start by mid-2027.
Key Highlights
- Kymera Therapeutics appointed Dr. Elizabeth Laws as Senior Vice President, KT-621 Development Program Leader.
- Dr. Laws previously served as SVP, Head of Sanofi Integrated Launch & Commercialization Excellence.
- She led global development strategy for Dupilumab/Dupixent® at Sanofi.
- KT-621 parallel Phase 2b trials are advancing in atopic dermatitis (AD) and asthma.
- Data for KT-621 in AD is expected by year-end 2026.
- Data for KT-621 in asthma is expected late 2027.
- Phase 3 trials for KT-621 in AD are planned to initiate by mid-2027.
Price Impact
More from KYMR